All In Biotech

Drug Trial Radar · NCT06948019

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

Safety and Efficacy of AAV9/AP4B1 For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration

Last checked: Nov 19, 2026Latest source record: Apr 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Aug 2030

Study completion Aug 2032

Sponsor

Lead sponsor
BlackfinBio LtdIndustry
Sponsor type
Industry
Collaborators
Boston Children's Hospital
First posted
Apr 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 60 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety and Efficacy of AAV9/AP4B1 For Patients with AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration. The goal of this clinical trial is to evaluate whether a gene therapy can safely treat children with SPG47, a rare genetic condition that causes progressive spasticity and developmental delays. The main questions it aims to answer are: * Is the gene therapy safe and well tolerated? * Does the gene therapy improve motor function and developmental outcomes? Participants will: * Undergo screening assessments to confirm eligibility * Receive a single dose of the gene therapy vector * Attend follow-up visits for safety monitoring and developmental assessments over the course of five years

Conditions

  • HSP
  • Hereditary Spastic Paraplegia
  • Hereditary Spastic Paraparesis
  • Hereditary Spastic Paraplegia Type 50
  • Hereditary Spastic Paraplegia Type 47
  • Hereditary Spastic Paraplegia Type 51
  • Hereditary Spastic Paraplegia Type 52
  • SPG47
  • AP4B1
  • Neurogenetic Disorders
  • Neurodevelopmental Conditions
  • Movement Disorders
  • Gene Therapy

Interventions

  • BFB-101 (AAV9-CBh-AP4B1)Biological

    The AAV9-CBh-AP4B1 biological drug product is an aqueous suspension of a gene transfer vector intended for CSF injection. It consists of replication deficient adeno-associated virus (AAV) vector with the AAV serotype 9 capsid enclosing a single stranded DNA with an expression cassette of AP4B1 driven by CBh promoter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of unanticipated treatment-related toxicities, Grade 3 or higher in participants with SPG47Time frame: 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.